Brought to you by 
Valeant pays €350mm cash for PharmaSwiss
08 Feb 2011
Executive Summary
Strengthening its position in the Central and Eastern European branded generics market, Valeant Pharmaceuticals International Inc. (neurology and dermatology therapies) has agreed to pay €350mm ($480mm) in cash to acquire privately held PharmaSwiss SA (generics and OTC products). The deal also includes the possibility of up to €30mm in sales-based earn-outs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com